Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19

Affiliations

¹ Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford OX3 7FZ, UK.
² Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Jonas Bovijn et al. Lancet Rheumatol. 2020 Nov.

. 2020 Nov;2(11):e658-e659.

doi: 10.1016/S2665-9913(20)30345-3. Epub 2020 Sep 25.

¹ Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford OX3 7FZ, UK.
² Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

No abstract available

References

1. Biran N, Ip A, Ahn J. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020 doi: 10.1016/S2665-9913(20)30277-0. published online Aug 14. - DOI - PMC - PubMed
1. Georgakis MK, Malik R, Gill D. Interleukin-6 signaling effects on ischemic stroke and other cardiovascular outcomes: a mendelian randomization study. Circ Genom Precis Med. 2020;13 - PMC - PubMed
1. COVID-19 Host Genetics Initiative The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet. 2020;28:715–718. - PMC - PubMed
1. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. Swerdlow DI, Holmes MV. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379:1214–1224. - PMC - PubMed
1. Regeneron Regeneron and Sanofi provide update on Kevzara (sarilumab) phase 3 U.S. trial in COVID-19 patients. July 2, 2020. https://investor.regeneron.com/news-releases/news-release-details/regene...